Drugs / Emtricitabine/Tenofovir disoproxil fumarate
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00608569 Background | Mar 2009 → Sep 2012 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine/Tenofovir disoproxil fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00608569 ↗ |
| Route | Oral | “200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily” NCT00608569 ↗ |